- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Neola Medical AB: Neola Medical Granted U.S. Design Patent Strengthening Protection of Neola User Interface | 217 | GlobeNewswire (Europe) | Neola Medical AB (publ) today announces that the United States Patent and Trademark Office (USPTO) has granted the company a design patent covering the graphical user interface of Neola®. The patent... ► Artikel lesen | |
| 20.08. | Neola Medical weitet Verlust in Q2 2026 aus - Aktie gibt nach | 5 | Investing.com Deutsch | ||
| 20.08. | Neola Medical AB Q2 Loss Widens | 2 | RTTNews | ||
| 20.08. | Neola Medical AB: Neola Medical Q2 Report 2026 - Clinical progress, secured financing and sharpened focus | 151 | GlobeNewswire (Europe) | During the quarter, Neola Medical reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The study confirmed a favorable safety profile of Neola® and... ► Artikel lesen | |
| 10.06. | Neola Medical AB: Neola Medical granted Patent in the U.S. for reducing optical noise in lung monitoring measurements | 168 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted a patent in the U.S. for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed to... ► Artikel lesen | |
| NEOLA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.06. | Listing of subscription rights and paid subscription shares of Neola Medical AB | 297 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Neola Medical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 19.05. | Neola Medical AB: Neola Medical Q1 Report 2026 - Positive safety results from clinical study in preterm born babies strengthen the path toward market | 210 | GlobeNewswire (Europe) | During the quarter, Neola Medical completed enrollment and reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The study confirmed a favorable safety... ► Artikel lesen | |
| 21.04. | Neola Medical AB: Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development | 169 | GlobeNewswire (Europe) | Neola Medical today announces final results from its clinical pilot study, confirming a favorable safety profile of Neola® across the studied patient population, including very low birth weight preterm... ► Artikel lesen | |
| 16.03. | Neola Medical AB: Neola Medical Completes Enrollment in Swedish Clinical Pilot Study | 412 | GlobeNewswire (Europe) | Neola Medical announces completion of patient enrollment in its clinical pilot study on preterm born babies in Sweden. All ten babies have now been included in the study, marking an important milestone... ► Artikel lesen | |
| 12.02. | Neola Medical AB: Neola Medical Q4 Report 2025 - Advancing IP Protection as a Core Strategic Asset across Key Markets | 188 | GlobeNewswire (Europe) | During the quarter four new patents were granted, adding in total of seven new patent grants during 2025. This marks Neola Medical's strongest year to date in terms of IP protection across all key target... ► Artikel lesen | |
| 02.12.25 | Neola Medical AB: Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market | 219 | GlobeNewswire (Europe) | Neola Medical AB (publ) announces today that the company has been granted a U.S. patent protecting its disposable probes for the medical device Neola®. The advanced light and detector probes are used... ► Artikel lesen | |
| 13.11.25 | Neola Medical AB: Neola Medical granted Patent in China for reducing optical noise in lung monitoring measurements | 238 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted its first patent in China for a technical solution that reduces noise in measurements for continuous lung monitoring. The patent protects an innovation designed... ► Artikel lesen | |
| 04.11.25 | Neola Medical AB: Neola Medical Q3 Report 2025 - Progressing toward completion of Swedish clinical pilot study and strengthening leadership team | 158 | GlobeNewswire (Europe) | During the quarter Neola Medical strengthened the leadership team with appointment of a Clinical Director. In addition, the company's IP portfolio was reinforced in Europe with a newly granted patent... ► Artikel lesen | |
| 04.11.25 | Neola Medical AB: Revised Timeline Announced as Clinical Pilot Study Indicates Robust Safety and Need for Optimization of Neola | 195 | GlobeNewswire (Europe) | Preliminary results from Neola Medical's ongoing clinical pilot study on preterm born babies indicate a robust safety profile of the medical device Neola®.
The preliminary findings indicate variations... ► Artikel lesen | |
| 16.10.25 | Neola Medical AB: Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola | 229 | GlobeNewswire (Europe) | Neola Medical AB (publ) has been granted patents in both the U.S. and China for a technical method that improve the accuracy of continuous lung monitoring with the company's medical device, Neola®.... ► Artikel lesen | |
| 25.09.25 | Neola Medical AB: Neola Medical strengthens leadership team with appointment of Clinical Director | 278 | GlobeNewswire (Europe) | Neola Medical AB (publ) is pleased to announce the appointment of Eva Bondesson as Clinical Director, effective October 1, 2025. As Neola Medical advances through the clinical phase, Eva Bondesson brings... ► Artikel lesen | |
| 10.09.25 | Neola Medical AB: Neola Medical granted European patent enabling lung monitoring beyond preterm born babies | 222 | GlobeNewswire (Europe) | Neola Medical AB (publ) announces today that the company has been granted a European patent for an invention aiming to enable lung monitoring in broader patient groups. This new patent complements the... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEARTFLOW | 50,53 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| GENEDX | 84,81 | 0,00 % | GeneDx study shows rapid genome sequencing benefits beyond ICUs | ||
| BILLIONTOONE | 92,32 | 0,00 % | Jim Cramer Calls BillionToOne (BLLN) a "Pretty Darn Good Company" | ||
| BRIGHTSPRING HEALTH SERVICES | 59,18 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,950 | -0,89 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,050 | -1,24 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,590 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| FRESENIUS | 44,180 | -1,35 % | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Fresenius, Gerresheimer, TUI und viele weitere Unternehmen präsentieren sich im Rahmen der SdK-Anlegerforen | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Konferenz/Konferenz
Fresenius, Gerresheimer, TUI und viele weitere Unternehmen präsentieren... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,585 | 0,00 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,465 | 0,00 % | Aveanna Healthcare Stock Offers Everything Investors Want as Shares Hit New All-Time High | ||
| PROGYNY | 25,680 | +0,08 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 20,630 | 0,00 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,920 | 0,00 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,200 | -1,53 % | 2,2 Milliarden Menschen mit Sehbeeinträchtigungen: Warum Augengesundheit für Carl Zeiss Meditec, Alcon & Co. zum Technologiemarkt wird - und wo Rise Nano Optics ins Spiel kommt | ||
| GUARDIAN PHARMACY SERVICES | 38,960 | 0,00 % | Guardian Pharmacy acquires assets from Nautilus Pharmacy |
Das Unternehmen NEOLA MEDICAL AB kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEOLA MEDICAL AB finden Sie auf Wallstreet Online.